Amedica Announces Presentation of 12-Month CASCADE Clinical Results
Amedica to Host Conference Call on March 24, 2015
SALT LAKE CITY, March 16, 2015 (GLOBE NEWSWIRE) -- Amedica Corporation (Nasdaq:AMDA), a company that develops and commercializes silicon nitride ceramics as a biomaterial platform, announced today that it will host a conference call and live webcast to present the 12-month CASCADE clinical results, a blinded, randomized clinical trial that compared outcomes of spinal fusion surgery between its composite silicon nitride fusion devices manufactured with a central core of cancellous structured ceramic (CsC), to the industry gold standard, i.e., PEEK (polyether ether ketone plastic) spacers filled with bone autograft.
Mark P. Arts, M.D., Ph.D., Neurosurgeon at the Medical Center Haaglanden, The Hague, Netherlands will present the findings and Dr. Sonny Bal, Chairman and CEO of Amedica Corporation will discuss the potential impact on the business. Details related to this call are as follows:
|Date:||Tuesday March 24, 2015|
|Time:||2:00 p.m. Eastern Time|
|Dial-in:||Toll-free (855) 455-6055|
|International (484) 756-4308|
For those who are not available to listen to the live webcast, the call will be archived on the investor relations section of the Amedica website under Events & Presentations.
About Amedica Corporation
Amedica is focused on the development and application of medical-grade silicon nitride ceramics. Amedica markets spinal fusion products and is developing a new generation of wear- and corrosion-resistant implant components for hip and knee arthroplasty. The Company manufactures its products in its ISO 13485 certified manufacturing facility and, through its partnership with Kyocera, the world's largest ceramic manufacturer. Amedica's spine products are FDA-cleared, CE-marked, and are currently marketed in the U.S. and select markets in Europe and South America through its distributor network and its growing OEM partnerships.
For more information on Amedica or its silicon nitride material platform, please visit www.amedica.com.
CONTACT: Mike Houston Director of Investor Relations 801-839-3534 email@example.com
Released March 16, 2015